On May 17, 2023 OmniNano Pharmaceuticals LLC, a developmental stage start-up company, reported that it has been awarded $2.7 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to develop ONP-001, OmniNano’s lead drug candidate, for treating pancreatic ductal adenocarcinoma (PDAC) (Press release, OmniNano Pharmaceuticals, MAY 17, 2023, View Source [SID1234656610]). 1 Pancreatic cancer is a devastating disease with a 5-year survival rate of just 12.5% and an overall median survival for PDAC of less than 12 months.2 Currently, no effective targeted therapy or immunotherapy is available for PDAC.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very excited to be awarded this SEED product development research grant. It validates the value of the patented platform technology and comprehensive lab and animal works already performed," says Guorong Ma, PhD, Chief Executive of OmniNano. "We are very appreciative to CPRIT and its review committee for recognizing our technology and proposed IND-enabling studies. This grant is critical for us to speed up our developmental work and facilitate further private investment. We are eager to advance our product, ONP-001, to the clinical trial phase to improve outcomes and extend life in pancreatic cancer patients, who are in desperate need of effective treatment."
ONP-001 consists of novel polymeric micelles encapsulating two naturally occurring drug compounds: one is an FDA-approved chemotherapeutic drug, and the other is capable of depleting cancer stem cells and modulating tumor stroma to overcome drug resistance, enhance drug delivery efficiency, and display significant antitumor activity on preclinical PDAC models.